Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06613698 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease
A Phase 2 study of Liver Diseases, Alcoholic, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 393
- Enrollment target
- 20
- Study locations
NCT06613698: Recruiting Phase 2 study of Liver Diseases, Alcoholic, sponsored by GlaxoSmithKline.
NCT06613698 is a Phase 2 study of Liver Diseases, Alcoholic that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 393 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (195% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06613698, a Phase 2 study of Liver Diseases, Alcoholic, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 393 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GSK4532990
Study Locations (20)
Arizona
- GSK Investigational Site - Chandler
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tucson
California
- GSK Investigational Site - Davis
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
Florida
- GSK Investigational Site - Brandon
- GSK Investigational Site - Miami Lakes
Texas
- GSK Investigational Site - Arlington
- GSK Investigational Site - Austin
Georgia
- GSK Investigational Site - Atlanta
Indiana
- GSK Investigational Site - Indianapolis
Kansas
- GSK Investigational Site - Topeka
Louisiana
- GSK Investigational Site - Marrero
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2028-03-30 |
| Phase | Phase 2 |
What NCT06613698 shows while recruiting
NCT06613698 is an interventional study that assigns participants to a tested intervention. The registered 393 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (195% higher).
The record links to 1 condition, with Liver Diseases, Alcoholic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06613698 names 20 study sites across 14 states, led by Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06613698 about?
NCT06613698 is a clinical study titled "A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease". The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
What is the current status of trial NCT06613698?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 393 participants. The study started on 2024-09-27. Estimated completion is 2028-03-30.
What conditions does trial NCT06613698 study?
This clinical trial studies the following conditions: Liver Diseases, Alcoholic.
What interventions are being tested in trial NCT06613698?
The interventions under investigation include: Placebo (DRUG), GSK4532990 (DRUG).
Who is sponsoring clinical trial NCT06613698?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06613698 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Diseases, Alcoholic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06613698's enrollment target sits among peer trials
393 104th of 2000 higher than 1,896 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- NCT06657924 · 394 participants · Phase 2
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
- NCT07225660 · 394 participants · NA
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI